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Hyperphosphorylation of microtubule-associated protein tau is one of the major patho-
logical events in Alzheimer’s disease (AD) and other related neurodegenerative diseases,
including frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
Mutations in the tau gene MAPT are a cause of FTDP-17, and the mutated tau proteins
are hyperphosphorylated in patient brains.Thus, it is important to determine the molecular
mechanism of hyperphosphorylation of tau to understand the pathology of these diseases
collectively called tauopathy.Tau is phosphorylated atmany sites via several protein kinases,
and a characteristic is phosphorylation at Ser/Thr residues in Ser/Thr-Pro sequences, which
are targeted by proline-directed protein kinases such as ERK, GSK3β, and Cdk5. Among
these kinases, Cdk5 is particularly interesting because it could be abnormally activated
in AD. Cdk5 is a member of the cyclin-dependent kinases (Cdks), but in contrast to the
major Cdks, which promote cell cycle progression in proliferating cells, Cdk5 is activated
in post-mitotic neurons via the neuron-speciﬁc activator p35. Cdk5-p35 plays a critical role
in brain development and physiological synaptic activity. In contrast, in disease brains,
Cdk5 is thought to be hyperactivated by p25, which is the N-terminal truncated form of
p35 and is generated by cleavage with calpain. Several reports have indicated that tau is
hyperphosphorylated by Cdk5-p25. However, normal and abnormal phosphorylation of tau
by Cdk5 is still not completely understood. In this article, we summarize the physiological
and pathological phosphorylation of tau via Cdk5.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenera-
tive dementia and affects more than 35 million people worldwide.
Thus, the development of therapeutic methods is urgently needed
to determine the underlying molecular mechanism of AD. Major
pathological hallmarks of AD include senile plaques and neuroﬁb-
rillary tangles (NFT), which consist mainly of amyloid β peptide
(Aβ) and hyperphosphorylated tau, respectively (Mattson, 1997;
Bettens et al., 2010). Mutations of the amyloid precursor protein
(APP) and presenilin, a component of γ-secretase, are found in
familial AD, and previous studies have established the hypothesis
of the amyloid cascade (Huse and Doms, 2000; Gotz et al., 2004;
Hardy, 2006; Bertram et al., 2010). On the basis of this hypoth-
esis, great effort has been paid to develop drugs to reduce Aβ
production or to clear Aβ, but successful results have not yet been
obtained. In contrast, it has been shown that tau pathology ismore
closely related to neuronal loss (Gómez-Isla et al., 1997; Ingels-
son et al., 2004). Tau is a genetic factor of a neurodegenerative
disease known as frontotemporal dementia parkinsonism linked
with chromosome 17 (FTDP-17; Hutton et al., 1998; Poorkaj et al.,
1998; Spillantini et al., 1998). FTDP-17 tau mutants are highly
phosphorylated in patient brains. Regardless of whether phos-
phorylation is a cause of FTDP-17, it is still critical to determine
the neuronal milieu in which tau hyperphosphorylation occurs.
Cyclin-dependent kinase 5 (Cdk5) is a major tau kinase that is
involved in abnormal phosphorylation in AD brains (Imahori and
Uchida, 1997; Cruz and Tsai, 2004; Engmann and Giese, 2009).
Here, we summarize the phosphorylation of tau by Cdk5. To
the best of our knowledge, this is the ﬁrst review article focused
speciﬁcally on Cdk5 phosphorylation of tau.
Tau PROTEIN
Tau is a member of the heat-stable microtubule-associated pro-
teins (MAPs), which consist of MAP2 and MAP4 (Dehmelt and
Halpain, 2005). Tau, as well as MAP2, is mainly expressed in mam-
malian neurons. While MAP2 is localized in dendrites, tau binds
to microtubules that are present in axons and is thus often used
as an axonal marker (Binder et al., 1985). Similar to MAP2, tau
binds to microtubules via the C-terminal microtubule-binding
repeats, which consist of three or four imperfect repeats of 31
or 32 amino acids. There are six isoforms in human tau (Goed-
ert et al., 1989) that are dependent on the presence or absence
of one or two N-terminal insertions and a C-terminal region
with three (3R) or four (4R) microtubule-binding repeats. The
longest isoform of human tau is composed of 441 amino acids;
the phosphorylation sites and mutation sites are usually num-
bered according to this isoform of tau (Figure 1). We also
used this notation in this article. Physiologically, tau promotes
microtubule assembly and stabilizes microtubules by laterally
binding to the surface of microtubules (Matus, 1994; Mandelkow
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FIGURE 1 | Frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17) mutation and phosphorylation sites in tau.
The longest human tau consists of 441 amino acids. Two N-terminal
insertions are labeled in yellow, the proline-rich region is labeled in green,
and four microtubule-binding repeats are shown in blue. FTDP-17 mutations
are shown above and the phosphorylation sites are shown below tau. All
phosphorylation sites reported thus far are indicated by arrowheads, and
the (Ser/Thr)Pro sequences, all Cdk5 phosphorylation sites, major Cdk5
phosphorylation sites and major GSK3β phosphorylation sites are shown in
the upper to lower row.
et al., 1995). In addition to the classical functions, new func-
tions in signaling and cytoskeletal organization have emerged
(Morris et al., 2011). These activities are regulated by phosphory-
lation in the microtubule-binding repeat or the franking region
by a number of protein kinases (Imahori and Uchida, 1997;
Johnson and Stoothoff, 2004; Gong and Iqbal, 2008; Avila et al.,
2010). Thus, the physiological function of tau is regulated by
phosphorylation. Tau is a naturally unfolded protein with an
extended structure but aggregates into NFTs in the brains of
AD patients. A number of neurodegenerative diseases with tau
aggregates are collectively known as tauopathy (Iqbal et al., 2005;
Spillantini and Goedert, 2013). Tau in aggregates is hyperphos-
phorylated, and this hyperphosphorylation is a feature employed
for the diagnosis of diseases. However, it is not completely
knownhowpathological tau is hyperphosphorylated andwhat role
hyperphosphorylation plays in aggregate formation and disease
development.
Cdk5 AS A tau PROTEIN KINASE
Cdk5 was ﬁrst puriﬁed as one (TPKII) of two tau protein kinases,
namelyTPKI andTPKII, fromabovine brainmicrotubule fraction
(Ishiguro et al., 1992), as neuronal cdc2-like kinase (nclk) from
bovine brain extracts (Lew et al., 1992), and as a KSP sequence
phosphorylating kinase from rat spinal cord (Shetty et al., 1993).
Puriﬁed Cdk5 is a complex that consists of the Cdk5 catalytic
subunit with a molecular mass of approximately 31 kDa and a
polypeptide with a molecular mass of approximately 23–25 kDa
(p25). p25 was subsequently shown to be an N-terminal trun-
cated form of its full-length version of p35 (Lew et al., 1994; Tsai
et al., 1994; Uchida et al., 1994). Cdk5 has attracted attention as
a potential disease tau kinase because Cdk5 phosphorylated tau
at sites that were hyperphosphorylated in AD brains (Imahori
and Uchida, 1997). Importantly, there is an accumulation of p25
in AD brains with higher phosphorylation ability of Cdk5-p25
for tau compared Cdk5 activated by p35 (Patrick et al., 1999),
which highlights the importance of Cdk5-p25 in abnormal tau
phosphorylation.
GENERAL PROPERTIES OF Cdk5
Cdk5 is amember of the Ser/Thr cyclin-dependent kinases (Cdks).
Cdk5 is a catalytic subunit and is activated by binding to its reg-
ulatory subunit, p35 or p39 (Figure 2). Cdk5 has a 55∼60%
amino acid sequence homology to well-known cell cycle Cdks
(Hellmich et al., 1992; Meyerson et al., 1992), such as Cdk1, 2,
4, and 6, but its activators, namely p35 and p39, display no
homology to cyclins, which are activators of cell cycle Cdks. p35
and p39 consist of 307 and 369 amino acids, respectively, with
a Cdk5 activation domain in the C-terminal region (Lew et al.,
1994; Tsai et al., 1994; Uchida et al., 1994; Tang et al., 1995; Zheng
et al., 1998). The crystal structure has revealed that the activation
domain of p35 has a tertiary structure, which resembles cyclin
A in the Cdk2-cyclin A complex, that explains its ability to acti-
vate Cdk5 (Tarricone et al., 2001). Although cell cycle Cdks are
activated at a particular cell cycle phase in proliferating cells and
promote cell cycle progression, Cdk5 is mainly active in post-
mitotic neurons, although Cdk5 is expressed widely in many cells
types and tissues. This is because p35 and p39 are predominantly
expressed in neurons (Lew et al., 1994; Tsai et al., 1994; Uchida
et al., 1994; Tang et al., 1995; Zheng et al., 1998). The number of
reports describing the kinase activity of Cdk5 in extra-neuronal
cells or tissues is increasing (Rosales and Lee, 2006), but the acti-
vation mechanism and function are poorly understood yet. While
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FIGURE 2 | Activation mechanism of Cdk5. Cdk5 alone is an inactive
catalytic subunit. Cdk5 is activated by the p35 Cdk5 activator and is
concomitantly recruited to membranes because p35 associates with
membranes via myristoylation of its N-terminal region. p35 is a protein with
a short-life span and is proteasomally degraded.When neurons suffer from
stress or encounter death signals, calpain is activated and cleaves p35 into
a p25 C-terminal fragment. p25 has a longer half-life and is dissociated from
membranes, where it is able to phosphorylate additional proteins.
p35 could be the major activator, cyclin I was indicated to be
an activator of Cdk5 in kidney podocytes (Brinkkoetter et al.,
2009).
Cdks are a family of proline-directed protein kinases (PDPKs)
that phosphorylate Ser or Thr residues followed by proline, that is,
Ser/Thr-Pro sequences. The substrate speciﬁcity of Cdk5 is very
similar to that of Cdk1-cyclin B (Hisanaga et al., 1995). There are at
least three different PDPKs, namely MAP kinases such as ERK1/2,
GSK3, and Cdks, but their substrate preferences are slightly dif-
ferent. Cdk5 prefers the (Ser/Thr)-Pro motif with a basic amino
acid at the secondC-terminal site, (Ser/Thr)-Pro-X-(Lys/Arg) (X is
any amino acid; Hisanaga et al., 1991, 1993; Beaudette et al., 1993;
Sharma et al., 1999). ERK1/2 phosphorylates Pro-X-(Ser/Thr)-
Pro sequences (Davis, 1993), and GSK3β can phosphorylate
(Ser/Thr)-(X)3-(pSer/pThr) with priming phosphorylation at +4
site in addition to (Ser/Thr)Pro sequences (Cohen and Frame,
2001).
In contrast to cell cycle Cdks, Cdk5 does not require phospho-
rylation of the Cdk5 subunit in the activation loop for activation.
Binding of the regulatory subunits p35 and p39 is sufﬁcient for
activation (Qi et al., 1995; Lee et al., 1997; Hisanaga and Endo,
2010). The kinase activity of Cdk5 is mainly determined by the
available protein amounts of p35 or p39 in neurons. p35 and p39
are proteins with a short life in which the half-life is about 30 min
and 120 min for p35 and p39, respectively (Patrick et al., 1998;
Saito et al., 1998; Patzke and Tsai, 2002; Minegishi et al., 2010).
p35 and p39 are degraded by the ubiquitin-proteasome system
as are other short half-life proteins. Thus, one major factor that
regulates Cdk5 activity is degradation of p35 and p39 via pro-
teasomal degradation. Phosphorylation at Thr138 in p35 by Cdk5
stimulates this degradation (Kamei et al., 2007). Because phospho-
rylation decreases with aging, the half-life of p35 becomes longer
in adult mouse brains; however, it is not known how the phos-
phorylation state is determined or the identity of the E3 ubiquitin
ligase for p35.
The cellular localization is also different between cell cycle Cdks
and Cdk5. While cell cycle Cdks are mainly present in the nucleus,
where they promote the cell cycle, active Cdk5 associates with
membranes in the cytoplasm. This is achieved by the membrane
binding properties of p35 and p39, which are myristoylated at the
N-terminal Gly (Figure 2; Patrick et al., 1999; Patzke and Tsai,
2002; Asada et al., 2008, 2012). There are excess amounts of Cdk5
compared to p35 and p39, and these free Cdk5 molecules are sol-
uble. The binding of p35 or p39 not only activates Cdk5, but
it also induces its membrane association. Membrane association
is also supported by Lys residues in the N-terminal p10 region
of p35 and p39 (+charge in p35 in Figure 2). This membrane
association may not only restrict its targets to proteins local-
ized to the submembranous regions but also prohibits its nuclear
translocation.
When neurons suffer from stress, death signals or overexcita-
tion, large inﬂuxes of Ca2+ enter into the cytoplasm, resulting
in the activation of the calcium-dependent protease calpain (Ono
and Sorimachi, 2012). Calpain cleaves p35 to p25, an N-terminal
truncated form that consists of the C-terminal Cdk5 activation
domain (Figure 2; Patrick et al., 1999; Kusakawa et al., 2000; Lee
et al., 2000). Subsequently, in contrast to Cdk5-p35, Cdk5-p25 is
released from the membranes and is capable of accessing proteins.
In addition, a component of Cdk5-p25 is known to enter into the
nucleus to activate the cell cycle machinery. Furthermore, Cdk5-
p25 acquires a longer half-life, resulting in the net activation of
Cdk5 (Patrick et al., 1999; Minegishi et al., 2010).
Cdk5 PHOSPHORYLATION SITES IN tau
Tau is phosphorylated at approximately 45 sites in AD brains
(Figure 1). Phosphorylation characteristically occurs at many
(Ser/Thr)-Pro sequences (Figure 1; Hasegawa et al., 1992;
Morishima-Kawashima et al., 1995). Among the 16 (Ser/Thr)-
Pro sequences in tau, Cdk5 phosphorylates 9–13 sites (Chauhan
et al., 2005; Hanger et al., 2009). However, the reported sites are
not always the same. Initially, Ishiguro’s group identiﬁed Ser202,
Thr205, Ser235, andSer404 asTPKII (Cdk5-p25) phosphorylation
sites using amino acid sequencing (Arioka et al., 1993). In addi-
tion, using puriﬁed nclk (Cdk5-p25), Paudel et al. (1993) reported
Ser195, Ser202, Thr205, Thr231, Ser235, Ser396, and Ser404. Illen-
berger et al. (1998) demonstrated Ser202, Thr205, Ser235, and
Ser404 to be major sites with Thr153 and Thr212 as minor sites in
in vitro Cdk5-p25 phosphorylated tau using 2D-phospho-peptide
mapping and mass spectrometry analysis. Phosphorylation sites
of human tau via in vitro recombinant Cdk5-p20 (shorter acti-
vation construct than p25) include Thr181, Thr205, Thr212,
Thr217, Ser396, and Ser404, which were determined using mass
spectrometry (Lund et al., 2001). Liu et al. (2002) reported that
Cdk5-p25 phosphorylates Tau at Thr181, Ser199, Ser202, Thr205,
Thr212, Ser214, Ser217, Thr231, Ser235, Ser396, and Ser404
using a repertoire of phospho-speciﬁc antibodies. Using NMR,
Landrieu et al. (2010, 2011) analyze tau phosphorylation by Cdk2-
cyclin A3 and Cdk5-p25; while Cdk2-cyclin A3 phosphorylated
Thr153, Ser199, Ser202, Thr205, Thr231, Ser235, and Ser404,
with high levels of phosphate incorporation at Ser202/Thr205
and Thr231/Ser235, Cdk5-p25 needed GSK3β for the same phos-
phorylation proﬁle with Cdk5-p25 providing Ser202, Thr205,
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Ser235, and Ser404 as major sites. We believe that these dif-
ferences in phosphorylation sites were due to the methods and
kinase preparations used for analysis. The use of phospho-speciﬁc
antibodies may detect minor phosphorylation sites, which are
sometimes below the detection level of biochemical methods.
Further, immunoblotting with phospho-speciﬁc antibodies has
a problem in quantiﬁcation of multiply phosphorylated proteins
(Prabakaran et al., 2011). Puriﬁcation or in vitro reconstruction of
active Cdk5 is also challenging. If the kinase activity is not sufﬁ-
ciently high, then the contribution of contaminating kinases may
present challenges.
We have determined the phosphorylation sites of tau using
2D phosphor-peptide mapping in vitro (Cdk5-p25 puriﬁed from
porcine brains) and in cultured cells (co-transfected Cdk5-p35 or
Cdk5-p25) and primary neurons (endogenous Cdk5-p35) using
isotope labeling methods (Wada et al., 1998; Sakaue et al., 2005;
Yotsumoto et al., 2009; Kimura et al., 2013). The major in vitro
Cdk5 phosphorylation sites determined were Ser202 or Thr205
(spot 2), Ser235 (spot 4), and Ser404 (spots 3 and 5; Figure 3A). A
similar in vitro 2D-phosphopeptide pattern has been reported by
Illenberger et al. (1998). These sites were detected as major sites
in cultured COS-7 cells when Cdk5-p25 was co-transfected and
in primary neurons (Figure 3A; Sakaue et al., 2005). These results
indicated that Cdk5 is a major kinase that phosphorylates tau in
cultured neurons. The signal of spot 1, which is a doubly phospho-
rylation spot of Ser202 and Thr205, is strong in cultured neurons
but weak when phosphorylated by Cdk5 in vitro. Interestingly,
Ser202 and Thr205 are exclusive phosphorylation sites for Cdk5,
but only one of these sites is phosphorylated, with a preference for
Ser202 by Cdk5 (Figure 3B; Kimura et al., 2013). However, both
sites can be phosphorylated by Cdk5 on the tau molecule when
FIGURE 3 | 2D-phosphopeptide mapping of tau phosphorylation by
Cdk5. (A) Comparison of phosphorylation spots between tau
phosphorylated in vitro via Cdk5-p35 (upper) and in cultured neurons
(middle). The lower panel is a merged image. Spot 1 is doubly
phosphorylated at Ser202 andThr205. Spot 2 is phosphorylated at Ser202
orThr205, spots 3 and 5 at Ser404 and spot 4 at Ser235. Spot 6, which was
found in rat cortical neurons (B), was missing in tau phosphorylated by
Cdk5-p35 in vitro (dotted square). The spot was not detected in T181A
mutant (Sakaue et al., 2005). Reproduced from Sakaue et al. (2005).
(B) 2D-phosphopeptide map of tauWT (upper left), tau S202A (upper right),
tau T205A (lower left), and tau S202A/T205A. Spot 1 corresponds to spot 2
of (A), spot 2 to spot 3 of (A), and spot 3 to spot 5 of (A). Reproduced from
Kimura et al. (2013).
bound on microtubules (Wada et al., 1998). The strong signal on
spot 1 in cultured neurons suggests that most tau in neurons binds
to microtubules or that the sites are phosphorylated by multiple
kinases.
According to the phosphorylation sites described above, the
(Ser/Thr)-Pro sequences in tau can be grouped into three cate-
gories: (1) major Cdk5 phosphorylation sites, (2) minor Cdk5
phosphorylation sites and (3) non-Cdk5 phosphorylation sites
(Figure 4). As tau is a ﬁlamentous protein, the amino acid
sequence around the phosphorylation sites may affect their phos-
phorylation ability more than those in globular proteins. Thus,
several interesting aspects can be observed; three of the four
major sites, speciﬁcally Ser202, Thr205 and Ser235, have Pro at
the second N-terminal site, that is, Pro-X-(Ser/Thr)-Pro, which is
also a consensus sequence for MAP kinase (Davis, 1993). Thus,
these sites may be commonly phosphorylated by MAP kinase.
Ser404 is a nearly perfect consensus of Cdk5. Four of the six
minor phosphorylation sites have Lys or Arg at the N-terminal
next to the phosphorylation sites: (Lys/Arg)-(Ser/Thr)-Pro. These
Lys-Ser-Pro (KSP) sequences are phosphorylation sites found in
neuroﬁlament H and M subunits (Hisanaga et al., 1993; Kesava-
pany et al., 2003), and phospho-speciﬁc antibodies for these
sites are known to react with phospho-tau (Nukina et al., 1987;
Lichtenberg-Kraag et al., 1992). In contrast to these phosphory-
lation sites, there are many acidic amino acids around non-Cdk5
phosphorylation sites (labeled in blue in Figure 4), except for
Thr175. These acidic amino acids may decrease the propen-
sity of phosphorylation. Thus, Cdk5 cannot phosphorylate the
(Ser/Thr)-Pro site if it is already phosphorylated. This ﬁnd-
ing is consistent with the exclusive relationship between Ser202
and Thr205 phosphorylation and may also explain why Ser231
FIGURE 4 | Amino acid sequences around the (Ser/Thr)Pro motif in
tau. Ser or Thr residues N-terminal next to Pro are in the center. Basic and
acidic amino acids are highlighted in red and blue, respectively.
Phosphorylation sites reported thus far have been underlined.
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and Ser199 are minor phosphorylation sites, as they have a
better Cdk5 phosphorylation site close to them. This is in
contrast to GSK3β, which requires priming phosphorylation
around the phosphorylation sites (Figure 1; Cohen and Frame,
2001).
The Cdk5 phosphorylation sites described above are the results
of in vitro or cultured cell experiments. However, we believe that
these properties can be applied to in vivo phosphorylation. As
described above, Ser404 appears to be a Cdk5-speciﬁc site. Ser404
is one of the most phosphorylated sites in rat brain indepen-
dent of whether the phosphorylation was examined using mass
spectroscopy or an anti-phospho-antibody (Arioka et al., 1993;
Watanabe et al., 1993; Yu et al., 2009), which suggest that Cdk5 is
a major tau kinase in normal brains. Indeed, knockdown of Cdk5
reduced tau phosphorylation at the PHF-13 site (Ser396/Ser404;
Piedrahita et al., 2010), and transgenic expression of p25 in mouse
brain increases tau phosphorylation at several sites, including AT8
and PHF-1 sites (Ahlijanian et al., 2000; Cruz et al., 2003; Noble
et al., 2003). In contrast, several reports argue against in vivo
Cdk5 phosphorylation of tau. For example, phosphorylation of
tau is not decreased in mice with a null mutation of p35 (Hallows
et al., 2003). Furthermore, an increase in overall tau phosphoryla-
tion was not detected in p25 transgenic mice (Takashima et al.,
2001; Plattner et al., 2006), although phosphorylation at spe-
ciﬁc sites such as Ser202 and Ser235 was shown to increase in
another p25 mouse model (Wen et al., 2008). Tau expressed in
yeast lacking the Cdk5 homolog Pho85 showed an increase, not
a decrease, in phosphorylation (Vandebroek et al., 2005). These
reports demonstrate GSK3β to be the predominant tau kinase
and its inhibition via Cdk5 (Hallows et al., 2003; Plattner et al.,
2006; Wen et al., 2008). However, one challenge is the lack of
methods used to speciﬁcally detect Cdk5 phosphorylated sites.
Phospho-speciﬁc antibodies have been used. The most frequently
used antibodies are AT-8 and PHF-1; however, these antibodies
require multiple phosphorylation for immunoreaction; for exam-
ple, for AT-8, it requires phosphorylation at Ser199 in addition
to Ser202 or Thr205 phosphorylation by Cdk5; for AT180, a
recent report indicates AT180 requires only Thr231 phosphory-
lation (Amniai et al., 2011) although it was often used as evidence
for phosphorylation at both Thr231 and Ser235; and for PHF-1,
it requires phosphorylation at Ser369 following Ser404 phospho-
rylation by Cdk5. Thus, speciﬁc tools for each Cdk5 site alone are
required.
ABNORMAL OR PATHOLOGICAL PHOSPHORYLATION OF tau
BY Cdk5
It is generally considered that phosphorylation of tau by Cdk5-
p35 is physiological and that phosphorylation by Cdk5-p25 is
pathological. Most in vitro experiments have been done using
Cdk5-p25 because puriﬁed Cdk5 is complexed with p25. Thus,
these results should include information on abnormal phospho-
rylation of tau. Nevertheless, the entity of hyperphosphorylation
is still unclear; is there an increase in the number of phospho-
rylation sites, an increase in the extent of phosphorylation at
these particular sites, or both? Two biochemical studies have
addressed the kinetics of tau phosphorylation using recombinant
Cdk5-p35 and Cdk5-p25 (Hashiguchi et al., 2002; Peterson et al.,
2010). However, both studies arrived at different conclusions. One
study showed a higher afﬁnity of Cdk5-p25 for tau compared to
Cdk5-p35 (Hashiguchi et al., 2002), while the other did not obtain
similar ﬁndings (Peterson et al., 2010). Considering the multiple
phosphorylation sites in tau with different amino acid sequences
surrounding the sites, it may be difﬁcult to determine the kinetic
parameters of tau phosphorylation in vitro. Cellular phospho-
rylation may be even more complicated and is affected by the
accessibility of Cdk5 activated by p35 and p25, phosphorylation
by other kinases and the binding of tau to microtubules. Our
simple comparison using 2D-phospho-peptide mapping indicates
that the major phosphorylation spots were similar between tau
phosphorylated by Cdk5-p35 and Cdk5-p25 (Sakaue et al., 2005).
On the basis of these results, we propose that Cdk5-dependent
abnormal phosphorylation represents an increase in the rate of
phosphorylation at the particular sites rather than an increase in
the number of sites.
An increase in phosphorylation by Cdk5 would further elevate
the total phosphorylation of tau by facilitating subsequent phos-
phorylation with GSK3β. GSK3β is another tau kinase, which is
also known as TPKI (Ishiguro et al., 1992). GSK3β phosphory-
lates Ser/Thr residues with priming phosphorylation at the +4
site, (Ser/Thr)-X3-(pSer/pThr). In fact, GSK3β phosphorylation
is considerably enhanced by prior phosphorylation with Cdk5
(Arioka et al., 1993; Sengupta et al., 1997; Li et al., 2006). Although
many GSK3β sites have been reported (Chauhan et al., 2005;
Hanger et al., 2009), the major sites are Ser199, Ser202, Thr231,
Ser396, Ser400, and Ser412 (Imahori and Uchida, 1997). Thr
231 and Ser396/Se400 are primed by phosphorylation at Ser235
and Ser404 by Cdk5, respectively (Li et al., 2006). Thus, Cdk5
would increase the total phosphorylation of tau with GSK3β in an
additive manner.
The net phosphorylation is a result of the balance between
phosphorylation and dephosphorylation. Hyperphosphoryla-
tion should be attained by either increased phosphorylation or
decreased dephosphorylation.What is the contributionof dephos-
phorylation? As previously reported (Sontag and Sontag, 2014),
protein phosphatase 2A is a major phosphatase for tau. The
dephosphorylation velocity of tau at Cdk5 sites is slower compared
to PKA phosphorylation sites (Yotsumoto et al., 2009), which
may, at least in part, be due to the stronger resistance of phos-
phorylation at the (Ser/Thr)Pro sites against PP2A-dependent
dephosphorylation compared to other sites. Dephosphorylation
at the (Ser/Thr)Pro sites is modulated by Pin1 peptidyl-prolyl
cis/trans isomerase (Lu et al., 1999). Pin1 changes the conforma-
tion of the peptide bond at proline from cis to trans (Lu et al.,
1996; Lu and Zhou, 2007; Driver et al., 2014), and the trans-
conformation is easily dephosphorylated by PP2A (Figure 5).
Dephosphorylation of Cdk5 phosphorylation sites at Ser202 and
Ser235 is delayed in the absence of Pin1 (Kimura et al., 2013). The
contribution of Pin1 in tau aggregate formation in AD has been
demonstrated in Pin1-deﬁcient mouse brains (Liou et al., 2003).
In addition to the four major Cdk5 sites, dephosphorylation at
Ser212 and Thr231 is also stimulated by Pin1 (Lu et al., 1999;
Smet et al., 2004), although it is recently shown that dephospho-
rylation of Thr231 is not Pin1-dependent (Landrieu et al., 2011).
There may be more (Ser/Thr)-Pro phosphorylation sites in which
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FIGURE 5 | Schematic representing the contribution of Pin1 to the
hyperphosphorylation of FTDP-17 mutant tau.Tau is phosphorylated by
Cdk5 (yellow) and subsequently by GSK3β (blue) at (Ser/Thr)Pro sites. Pin1
changes the conformation of the peptide bond at p(Ser/Thr)Pro from cis to
trans, thereby facilitating its dephosphorylation with PP2A. FTDP-17 mutants
have a weak afﬁnity to Pin1 compared toWT tau.
dephosphorylation is regulated by Pin1. We also demonstrated
that phosphorylation of FTDP-17 mutant tau, P301L and R406W,
byCdk5 exhibits a slightly weaker afﬁnity to Pin1 compared toWT
tau, which may result in decreased dephosphorylation of mutant
tau by PP2A, consistent with previous reports that the FTDP
mutation demonstrates weakened binding to PP2A (Goedert et al.,
2000).
PHOSPHORYLATION OF FTDP-17 tau MUTANTS BY Cdk5
Frontotemporal dementia with parkinsonism linked to chromo-
some 17 is a dominantly inherited disease of neurodegenerative
dementia with mutations in the tau gene MAPT (Hutton et al.,
1998; Poorkaj et al., 1998; Spillantini et al., 1998). There are more
than 40 FTDP-17 mutations reported, most of which are missense
mutations found in the microtubule binding repeats with four
mutations at the N-terminal and six in the C-terminal regions
(Figure 1; Spillantini and Goedert, 2013). FTDP-17 mutant tau
forms aggregates in the frontal cortex of patient brains and tau is
abnormally phosphorylated at the sites of phosphorylation in AD
(Crowther and Goedert, 2000; Lee et al., 2005). Thus, it is thought
that these mutations are highly involved in abnormal phospho-
rylation. Phosphorylation of FTDP-17 mutants has been studied
predominantly in mice overexpressing mutant tau. Overexpressed
mutant tau forms sarkosyl-insoluble aggregates in mouse brains,
and aggregates can be labeled using phospho-speciﬁc antibod-
ies (Lewis et al., 2000; Gotz et al., 2001; Tanemura et al., 2002;
Tatebayashi et al., 2002; Ikeda et al., 2005; Yoshiyama et al., 2007).
However, similar to AD tau, it is not known how FTDP-17
mutation induces abnormal phosphorylation.
Several groups have examined the phosphorylation of FTDP-
17 tau mutants by Cdk5. Han et al. (2009) showed that mutations
of P301L, V337M, R406W, and G272V promoted the mobility
shift of tau upon phosphorylation by Cdk5, whereas R406W
inhibited Ser404 and Ser235 phosphorylation. They concluded
that the increased mobility shift was due to an increase in
phosphorylation at Ser202, Ser404, and Ser235 but not due to
the higher extent of total phosphorylation. Vanhelmont et al.
(2010) studied the phosphorylation of six FTDP-17 mutants,
namely G272D, N279K, K280, P301L, V337M, and R406W, in
yeast strains lacking mds1 GSK3β homolog and/or Pho85 Cdk5
homolog. They demonstrated that P301L and R406W showed
lower AD2 (phosphorylation at Ser396/Ser404) and PG5 (phos-
phorylation at Ser409) reactivity and that the reactionwas reduced
in the mds1-lacking strain and stimulated in the Pho85-deﬁcient
strain, suggesting that Ser396/Ser404 sites are phosphorylated
by GSK3β and mutations affecting Ser409 phosphorylation. We
have examined the phosphorylation of K257T, P301L, P301S,
and R406W mutants in vitro and in cultured cells by Cdk5
using 2D-phosphopeptide mapping (Sakaue et al., 2005; Yot-
sumoto et al., 2009). The phospho-peptide patterns were identical
between WT and mutant tau except for R406W. Phosphory-
lation at Ser404 was lacking in R406W. We propose that the
R406W mutation alters the preferred consensus at the Ser404
site for Cdk5 to less preferred sequences. A distinct differ-
ence in phosphorylation was consistently reported with R406W
tau, although these results were variable; reduced phospho-
rylation at many phosphorylation sites (DeTure et al., 2002),
reduced phosphorylation at speciﬁc sites (Alonso Adel et al., 2004;
Gauthier-Kemper et al., 2011), or greater overall phosphorylation
was observed (Krishnamurthy and Johnson, 2004). One R406W
patient showed a different progression of the disease from other
FTDP-17 patients. Thus, it would be interesting to determine
the role of this speciﬁc property of phosphorylation in disease
development.
INSULT-INDUCED PHOSPHORYLATION OF tau BY Cdk5 IN
BRAINS
Numerous reports have described an increased phosphorylation
of tau when neurons suffer from various neurotoxic insults, such
as Aβ (Otth et al., 2002; Han et al., 2005; Zheng et al., 2005,
2010; Lopes et al., 2007; Zempel et al., 2010; Shukla et al., 2012),
ischemia/hypoxia (Wen et al., 2007; Barros-Miñones et al., 2013),
oxidative stress (Absalon et al., 2013), inﬂammation (Quintanilla
et al., 2004; Kitazawa et al., 2005), and excitotoxicity (Ho et al.,
2002). Aging may also represent a speciﬁc stress factor (Kelle-
her et al., 2007). Many of these studies observed an increase in
p25 and argued Cdk5-dependent phosphorylation of tau. How-
ever, the increase in p25 and tau phosphorylation were performed
in parallel and their direct correlation was not mostly demon-
strated. Considering that Cdk5 sites can be phosphorylated by
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other PDPKs and that relatively minor phosphorylation sites were
examined using western blotting analyses with anti-phospho-
speciﬁc antibodies, further studies are required to determine their
causal relationship.
CONCLUSION
Elucidation of themolecularmechanism inducing hyperphospho-
rylation of tau in tauopathic brains including AD is one of the
critical issues for the prevention of dementia development inde-
pendent of hyperphosphorylation as a cause of disease. Hyper-
phosphorylation must reﬂect the cellular conditions of affected
neurons in disease brains. Cdk5has been extensively studied as one
of themajor kinases because Cdk5 generates disease-speciﬁc phos-
phorylation epitopes. However, despite intensive previous studies,
it is still unclear how Cdk5 contributes to tau phosphorylation
physiologically and pathologically. In particular, in vivo phospho-
rylation by Cdk5 has not been convincingly demonstrated. This
may, at least in part, be due to an overlap in the phosphoryla-
tion of many (Ser/Thr)Pro sites in tau by several PDPKs. Another
possibility is the lack of methods used to speciﬁcally identify
Cdk5 phosphorylation. By overcoming these challenges, studies
on tau phosphorylation by Cdk5 can provide valuable insight on
the molecular mechanism underlying AD and the development of
strategies to prevent dementia.
REFERENCES
Absalon, S., Kochanek, D. M., Raghavan,V., and Krichevsky, A. M. (2013). MiR-26b,
upregulated inAlzheimer’s disease, activates cell cycle entry, tau-phosphorylation,
and apoptosis in postmitotic neurons. J. Neurosci. 33, 14645–14659. doi:
10.1523/JNEUROSCI.1327-13.2013
Ahlijanian, M. K., Barrezueta, N. X., Williams, R. D., Jakowski, A., Kowsz, K. P.,
McCarthy, S., et al. (2000). Hyperphosphorylated tau and neuroﬁlament and
cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.
Proc. Natl. Acad. Sci. U.S.A. 97, 2910–2915. doi: 10.1073/pnas.040577797
Alonso Adel, C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2004).
Promotion of hyperphosphorylation by frontotemporal dementia tau mutations.
J. Biol. Chem. 279, 34873–34881. doi: 10.1074/jbc.M405131200
Amniai, L., Lippens, G., and Landrieu, I. (2011). Characterization of the AT180 epi-
tope of phosphorylated Tau protein by a combined nuclear magnetic resonance
and ﬂuorescence spectroscopy approach. Biochem. Biophys. Res. Commun. 412,
743–746. doi: 10.1016/j.bbrc.2011.08.046
Arioka, M., Tsukamoto, M., Ishiguro, K., Kato, R., Sato, K., Imahori, K.,
et al. (1993). Tau protein kinase II is involved in the regulation of the nor-
mal phosphorylation state of tau protein. J. Neurochem. 60, 461–468. doi:
10.1111/j.1471-4159.1993.tb03173.x
Asada, A., Saito, T., and Hisanaga, S. (2012). Phosphorylation of p35 and p39 by
Cdk5 determines the subcellular location of the holokinase in a phosphorylation-
site-speciﬁc manner. J. Cell Sci. 125, 3421–3429. doi: 10.1242/jcs.100503
Asada, A., Yamamoto, N., Gohda, M., Saito, T., Hayashi, N., and Hisanaga, S.
(2008). Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear
localization of active cyclin-dependent kinase 5 complexes. J. Neurochem. 106,
1325–1336. doi: 10.1111/j.1471-4159.2008.05500.x
Avila, J., Gomez de Barreda, E., Engel, T., Lucas, J. J., and Hernandez, F. (2010). Tau
phosphorylation in hippocampus results in toxic gain-of-function. Biochem. Soc.
Trans. 38, 977–980. doi: 10.1042/BST0380977
Barros-Miñones, L., Martin-de-Saavedra, D., Perez-Alvarez, S., Orejana, L.,
Suquia, V., Goni-Allo, B., et al. (2013). Inhibition of calpain-regulated
p35/cdk5 plays a central role in sildenaﬁl-induced protection against chemi-
cal hypoxia produced by malonate. Biochim. Biophys. Acta 1832, 705–717. doi:
10.1016/j.bbadis.2013.02.002
Beaudette, K. N., Lew, J., and Wang, J. H. (1993). Substrate speciﬁcity characteriza-
tion of a cdc2-like protein kinase puriﬁed from bovine brain. J. Biol. Chem. 268,
20825–20830.
Bertram, L., Lill, C. M., and Tanzi, R. E. (2010). The genetics of Alzheimer disease:
back to the future. Neuron 68, 270–281. doi: 10.1016/j.neuron.2010.10.013
Bettens, K., Sleegers, K., and Van Broeckhoven, C. (2010). Current status on
Alzheimer disease molecular genetics: from past, to present, to future. Hum.
Mol. Genet. 19, R4–R11. doi: 10.1093/hmg/ddq142
Binder, L. I., Frankfurter, A., and Rebhun, L. I. (1985). The distribution of tau
in the mammalian central nervous system. J. Cell Biol. 101, 1371–1378. doi:
10.1083/jcb.101.4.1371
Brinkkoetter, P. T., Olivier, P., Wu, J. S., Henderson, S., Krofft, R. D., Pippin, J. W.,
et al. (2009). Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL
in postmitotic mouse cells. J. Clin. Invest. 119, 3089–3101. doi: 10.1172/JCI37978
Chauhan, N. B., Siegel, G. J., and Feinstein, D. L. (2005). Propentofylline atten-
uates tau hyperphosphorylation in Alzheimer’s Swedish mutant model Tg2576.
Neuropharmacology 48, 93–104. doi: 10.1016/j.neuropharm.2004.09.014
Cohen, P., and Frame, S. (2001). The renaissance of GSK3. Nat. Rev. Mol. Cell Biol.
2, 769–776. doi: 10.1038/35096075
Crowther,R.A., andGoedert,M. (2000). Abnormal tau-containingﬁlaments inneu-
rodegenerative diseases. J. Struct. Biol. 130, 271–279. doi: 10.1006/jsbi.2000.4270
Cruz, J. C., and Tsai, L. H. (2004). Cdk5 deregulation in the pathogenesis of
Alzheimer’s disease. Trends Mol. Med. 10, 452–458. doi: 10.1016/j.molmed.
2004.07.001
Cruz, J. C., Tseng, H. C., Goldman, J. A., Shih, H., and Tsai, L. H. (2003).
Aberrant Cdk5 activation by p25 triggers pathological events leading to neu-
rodegeneration and neuroﬁbrillary tangles. Neuron 40, 471–483. doi: 10.1016/
S0896-6273(03)00627-5
Davis, R. J. (1993). The mitogen-activated protein kinase signal transduction
pathway. J. Biol. Chem. 268, 14553–14556.
Dehmelt, L., and Halpain, S. (2005). The MAP2/Tau family of microtubule-
associated proteins. Genome Biol. 6, 204. doi: 10.1186/gb-2004-6-1-204
DeTure, M., Ko, L. W., Easson, C., and Yen, S. H. (2002). Tau assembly in inducible
transfectants expressingwild-type or FTDP-17 tau. Am. J. Pathol. 161, 1711–1722.
doi: 10.1016/S0002-9440(10)64448-3
Driver, J.A., Zhou,X. Z., and Lu,K. P. (2014). Regulation of protein conformation by
Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer’s
disease. Discov. Med. 17, 93–99.
Engmann, O., and Giese, K. P. (2009). Crosstalk between Cdk5 and GSK3β: impli-
cations for Alzheimer’s disease. Front. Mol. Neurosci. 2:2. doi: 10.3389/neuro.
02.002.2009
Gauthier-Kemper, A., Weissmann, C., Golovyashkina, N., Sebo-Lemke, Z., Drewes,
G., Gerke,V., et al. (2011). The frontotemporal dementia mutation R406W blocks
tau’s interaction with the membrane in an annexin A2-dependent manner. J. Cell
Biol. 192, 647–661. doi: 10.1083/jcb.201007161
Goedert, M., Satumtira, S., Jakes, R., Smith, M. J., Kamibayashi, C., White, C. L.
III, et al. (2000). Reduced binding of protein phosphatase 2A to tau protein with
frontotemporal dementia andparkinsonism linked to chromosome17mutations.
J. Neurochem. 75, 2155–2162. doi: 10.1046/j.1471-4159.2000.0752155.x
Goedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J., and Crowther, R. A. (1989).
Cloning and sequencing of the cDNA encoding an isoform of microtubule-
associated protein tau containing four tandem repeats: differential expression
of tau protein mRNAs in human brain. EMBO J. 8, 393–399.
Gómez-Isla, T., Wasco, W., Pettingell, W. P., Gurubhagavatula, S., Schmidt, S. D.,
Jondro, P. D., et al. (1997). A novel presenilin-1 mutation: increased beta-amyloid
and neuroﬁbrillary changes. Ann. Neurol. 41, 809–813. doi: 10.1002/ana.410
410618
Gong, C. X., and Iqbal, K. (2008). Hyperphosphorylation of microtubule-associated
protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med.
Chem. 15, 2321–2328. doi: 10.2174/092986708785909111
Gotz, J., Chen, F., Barmettler, R., and Nitsch, R. M. (2001). Tau ﬁlament forma-
tion in transgenic mice expressing P301L tau. J. Biol. Chem. 276, 529–534. doi:
10.1074/jbc.M006531200
Gotz, J., Schild, A., Hoerndli, F., and Pennanen, L. (2004). Amyloid-induced
neuroﬁbrillary tangle formation in Alzheimer’s disease: insight from trans-
genic mouse and tissue-culture models. Int. J. Dev. Neurosci. 22, 453–465. doi:
10.1016/j.ijdevneu.2004.07.013
Hallows, J. L., Chen, K., DePinho, R. A., and Vincent, I. (2003). Decreased cyclin-
dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and
cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35
null mice. J. Neurosci. 23, 10633–10644.
Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 65 | 7
Kimura et al. Phosphorylation of tau by Cdk5
Han, D., Qureshi, H. Y., Lu,Y., and Paudel, H. K. (2009). Familial FTDP-17 missense
mutations inhibit microtubule assembly-promoting activity of tau by increas-
ing phosphorylation at Ser202 in vitro. J. Biol. Chem. 284, 13422–13433. doi:
10.1074/jbc.M901095200
Han, P., Dou, F., Li, F., Zhang, X., Zhang, Y. W., Zheng, H., et al. (2005). Sup-
pression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a
novel excitoprotective mechanism involving modulation of tau phosphorylation.
J. Neurosci. 25, 11542–11552. doi: 10.1523/JNEUROSCI.3831-05.2005
Hanger, D. P., Anderton, B. H., and Noble, W. (2009). Tau phosphorylation: the
therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112–
119. doi: 10.1016/j.molmed.2009.01.003
Hardy, J. (2006). Has the amyloid cascade hypothesis for Alzheimer’s disease been
proved? Curr. Alzheimer Res. 3, 71–73. doi: 10.2174/156720506775697098
Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., and
Ihara, Y. (1992). Protein sequence and mass spectrometric analyses of tau in the
Alzheimer’s disease brain. J. Biol. Chem. 267, 17047–17054.
Hashiguchi, M., Saito, T., Hisanaga, S., and Hashiguchi, T. (2002). Trunca-
tion of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205
of human tau. J. Biol. Chem. 277, 44525–44530. doi: 10.1074/jbc.M2074
26200
Hellmich, M. R., Pant, H. C., Wada, E., and Battey, J. F. (1992). Neuronal cdc2-like
kinase: a cdc2-related protein kinase with predominantly neuronal expression.
Proc. Natl. Acad. Sci. U.S.A. 89, 10867–10871. doi: 10.1073/pnas.89.22.10867
Hisanaga, S., and Endo, R. (2010). Regulation and role of cyclin-dependent kinase
activity in neuronal survival and death. J. Neurochem. 115, 1309–1321. doi:
10.1111/j.1471-4159.2010.07050.x
Hisanaga, S., Ishiguro, K., Uchida, T., Okumura, E., Okano, T., and Kishimoto,
T. (1993). Tau protein kinase II has a similar characteristic to cdc2 kinase for
phosphorylating neuroﬁlament proteins. J. Biol. Chem. 268, 15056–15060.
Hisanaga, S., Kusubata, M., Okumura, E., and Kishimoto, T. (1991). Phosphoryla-
tion of neuroﬁlament H subunit at the tail domain by CDC2 kinase dissociates
the association to microtubules. J. Biol. Chem. 266, 21798–21803.
Hisanaga, S., Uchiyama, M., Hosoi, T., Yamada, K., Honma, N., Ishiguro, K.,
et al. (1995). Porcine brain neuroﬁlament-H tail domain kinase: its identiﬁca-
tion as cdk5/p26 complex and comparison with cdc2/cyclin B kinase. Cell Motil.
Cytoskeleton 31, 283–297. doi: 10.1002/cm.970310405
Ho, P. I., Ortiz, D., Rogers, E., and Shea, T. B. (2002). Multiple aspects of homo-
cysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA
damage. J. Neurosci. Res. 70, 694–702. doi: 10.1002/jnr.10416
Huse, J. T., and Doms, R. W. (2000). Closing in on the amyloid cascade: recent
insights into the cell biology of Alzheimer’s disease. Mol. Neurobiol. 22, 81–98.
doi: 10.1385/MN:22:1-3:081
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al.
(1998). Association of missense and 5′-splice-site mutations in tau with the
inherited dementia FTDP-17. Nature 393, 702–705. doi: 10.1038/31508
Ikeda, M., Shoji, M., Kawarai, T., Kawarabayashi, T., Matsubara, E., Murakami, T.,
et al. (2005). Accumulation of ﬁlamentous tau in the cerebral cortex of human
tau R406W transgenic mice. Am. J. Pathol. 166, 521–531. doi: 10.1016/S0002-
9440(10)62274-2
Illenberger, S., Zheng-Fischhofer, Q., Preuss, U., Stamer, K., Baumann, K., Trinczek,
B., et al. (1998). The endogenous and cell cycle-dependent phosphorylation of
tau protein in living cells: implications for Alzheimer’s disease. Mol. Biol. Cell 9,
1495–1512. doi: 10.1091/mbc.9.6.1495
Imahori, K., and Uchida, T. (1997). Physiology and pathology of tau protein kinases
in relation to Alzheimer’s disease. J. Biochem. 121, 179–188.
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley-Whyte, E.
T., Frosch, M. P., et al. (2004). Early Aβ accumulation and progressive synaptic
loss, gliosis, and tangle formation in AD brain. Neurology 62, 925–931. doi:
10.1212/01.WNL.0000115115.98960.37
Iqbal, K., Alonso Adel, C., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C. X.,
et al. (2005). Tau pathology in Alzheimer disease and other tauopathies. Biochim.
Biophys. Acta 1739, 198–210. doi: 10.1016/j.bbadis.2004.09.008
Ishiguro, K.,Omori,A., Takamatsu,M., Sato, K.,Arioka,M.,Uchida, T., et al. (1992).
Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase
generating an epitope of paired helical ﬁlaments. Neurosci. Lett. 148, 202–206.
doi: 10.1016/0304-3940(92)90839-Y
Johnson, G. V., and Stoothoff, W. H. (2004). Tau phosphorylation in neuronal cell
function and dysfunction. J. Cell Sci. 117, 5721–5729. doi: 10.1242/jcs.01558
Kamei, H., Saito, T., Ozawa, M., Fujita, Y., Asada, A., Bibb, J. A., et al. (2007).
Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by
site-speciﬁc phosphorylation. J. Biol. Chem. 282, 1687–1694. doi: 10.1074/jbc.
M610541200
Kelleher, I., Garwood, C., Hanger, D. P., Anderton, B. H., and Noble, W. (2007).
Kinase activities increase during the development of tauopathy in htau mice. J.
Neurochem. 103, 2256–2267. doi: 10.1111/j.1471-4159.2007.04930.x
Kesavapany, S., Li, B. S., and Pant, H. C. (2003). Cyclin-dependent kinase 5 in
neuroﬁlament function and regulation. Neurosignals 12, 252–264. doi: 10.1159/
000074627
Kimura, T., Tsutsumi, K., Taoka, M., Saito, T., Masuda-Suzukake, M., Ishiguro,
K., et al. (2013). Isomerase Pin1 stimulates dephosphorylation of tau protein at
cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites. J.
Biol. Chem. 288, 7968–7977. doi: 10.1074/jbc.M112.433326
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., and LaFerla, F. M. (2005).
Lipopolysaccharide-induced inﬂammation exacerbates tau pathology by a cyclin-
dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s
disease. J. Neurosci. 25, 8843–8853. doi: 10.1523/JNEUROSCI.2868-05.2005
Krishnamurthy, P. K., and Johnson, G. V. (2004). Mutant (R406W) human tau
is hyperphosphorylated and does not efﬁciently bind microtubules in a neu-
ronal cortical cell model. J. Biol. Chem. 279, 7893–7900. doi: 10.1074/jbc.M31
1203200
Kusakawa, G., Saito, T., Onuki, R., Ishiguro, K., Kishimoto, T., and Hisanaga,
S. (2000). Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent
kinase 5 activator to p25. J. Biol. Chem. 275, 17166–17172. doi: 10.1074/jbc.
M907757199
Landrieu, I., Leroy, A., Smet-Nocca, C., Huvent, I., Amniai, L., Hamdane, M.,
et al. (2010). NMR spectroscopy of the neuronal tau protein: normal function
and implication in Alzheimer’s disease. Biochem. Soc. Trans. 38, 1006–1011. doi:
10.1042/BST0381006
Landrieu, I., Smet-Nocca, C., Amniai, L., Louis, J. V., Wieruszeski, J. M., Goris, J.,
et al. (2011). Molecular implication of PP2A and Pin1 in the Alzheimer’s disease
speciﬁc hyperphosphorylation of Tau. PLoS ONE 6:e21521. doi: 10.1371/journal.
pone.0021521
Lee, K. Y., Qi, Z., Yu, Y. P., and Wang, J. H. (1997). Neuronal Cdc2-like kinases:
neuron-speciﬁc forms of Cdk5. Int. J. Biochem. Cell Biol. 29, 951–958. doi:
10.1016/S1357-2725(97)00048-4
Lee, M. S., Kwon, Y. T., Li, M., Peng, J., Friedlander, R. M., and Tsai, L. H. (2000).
Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360–364.
doi: 10.1038/35012636
Lee, V. M., Kenyon, T. K., and Trojanowski, J. Q. (2005). Transgenic ani-
mal models of tauopathies. Biochim. Biophys. Acta 1739, 251–259. doi:
10.1016/j.bbadis.2004.06.014
Lew, J., Beaudette, K., Litwin, C. M., and Wang, J. H. (1992). Puriﬁcation and
characterization of a novel proline-directed protein kinase from bovine brain. J.
Biol. Chem. 267, 13383–13390.
Lew, J., Huang, Q. Q., Qi, Z., Winkfein, R. J., Aebersold, R., Hunt, T., et al. (1994). A
brain-speciﬁc activator of cyclin-dependent kinase 5. Nature 371, 423–426. doi:
10.1038/371423a0
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst,
M., et al. (2000). Neuroﬁbrillary tangles, amyotrophy and progressive motor
disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25,
402–405. doi: 10.1038/78078
Li, T.,Hawkes, C.,Qureshi,H.Y., Kar, S., andPaudel,H.K. (2006). Cyclin-dependent
protein kinase 5 primes microtubule-associated protein tau site-speciﬁcally for
glycogen synthase kinase 3β. Biochemistry 45, 3134–3145. doi: 10.1021/bi051635j
Lichtenberg-Kraag, B., Mandelkow, E. M., Biernat, J., Steiner, B., Schroter, C.,
Gustke, N., et al. (1992). Phosphorylation-dependent epitopes of neuroﬁlament
antibodies on tau protein and relationship with Alzheimer tau. Proc. Natl. Acad.
Sci. U.S.A. 89, 5384–5388. doi: 10.1073/pnas.89.12.5384
Liou, Y. C., Sun, A., Ryo, A., Zhou, X. Z., Yu, Z. X., Huang, H. K., et al.
(2003). Role of the prolyl isomerase Pin1 in protecting against age-dependent
neurodegeneration. Nature 424, 556–561. doi: 10.1038/nature01832
Liu, F., Iqbal, K., Grundke-Iqbal, I., andGong, C. X. (2002). Involvement of aberrant
glycosylation in phosphorylation of tau by cdk5 and GSK-3β. FEBS Lett. 530,
209–214. doi: 10.1016/S0014-5793(02)03487-7
Lopes, J. P.,Oliveira, C. R., andAgostinho, P. (2007). Role of cyclin-dependent kinase
5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides:
Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 65 | 8
Kimura et al. Phosphorylation of tau by Cdk5
implications for Alzheimer’s disease and prion-related encephalopathies. Cell.
Mol. Neurobiol. 27, 943–957. doi: 10.1007/s10571-007-9224-3
Lu, K. P., Hanes, S. D., and Hunter, T. (1996). A human peptidyl-prolyl isomerase
essential for regulation of mitosis. Nature 380, 544–547. doi: 10.1038/380544a0
Lu, K. P., and Zhou, X. Z. (2007). The prolyl isomerase PIN1: a pivotal new twist in
phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol. 8, 904–916. doi:
10.1038/nrm2261
Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P., and Lu, K. P. (1999). The prolyl isomerase
Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.
Nature 399, 784–788. doi: 10.1038/21650
Lund, E. T., McKenna, R., Evans, D. B., Sharma, S. K., and Mathews, W. R. (2001).
Characterization of the in vitro phosphorylation of human tau by tau protein
kinase II (cdk5/p20) using mass spectrometry. J. Neurochem. 76, 1221–1232. doi:
10.1046/j.1471-4159.2001.00130.x
Mandelkow, E. M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B., and
Mandelkow, E. (1995). Tau domains, phosphorylation, and interactions
with microtubules. Neurobiol. Aging 16, 355–362; discussion 362–353. doi:
10.1016/0197-4580(95)00025-A
Mattson, M. P. (1997). Cellular actions of beta-amyloid precursor protein and its
soluble and ﬁbrillogenic derivatives. Physiol. Rev. 77, 1081–1132.
Matus, A. (1994). Stiff microtubules and neuronal morphology. Trends Neurosci. 17,
19–22. doi: 10.1016/0166-2236(94)90030-2
Meyerson, M., Enders, G. H.,Wu, C. L., Su, L. K., Gorka, C., Nelson, C., et al. (1992).
A family of human cdc2-related protein kinases. EMBO J. 11, 2909–2917.
Minegishi, S., Asada, A., Miyauchi, S., Fuchigami, T., Saito, T., and Hisanaga, S.
(2010). Membrane association facilitates degradation and cleavage of the cyclin-
dependent kinase 5 activators p35 and p39. Biochemistry 49, 5482–5493. doi:
10.1021/bi100631f
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida,
H., Titani, K., et al. (1995). Proline-directed and non-proline-directed phos-
phorylation of PHF-tau. J. Biol. Chem. 270, 823–829. doi: 10.1074/jbc.270.
2.823
Morris, M., Maeda, S., Vossel, K., and Mucke, L. (2011). The many faces of tau.
Neuron 70, 410–426. doi: 10.1016/j.neuron
Noble,W., Olm,V., Takata, K., Casey, E.,Mary,O.,Meyerson, J., et al. (2003). Cdk5 is
a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555–565.
doi: 10.1016/S0896-6273(03)00259-9
Nukina, N., Kosik, K. S., and Selkoe, D. J. (1987). Recognition of Alzheimer
paired helical ﬁlaments by monoclonal neuroﬁlament antibodies is due to cross-
reaction with tau protein. Proc. Natl. Acad. Sci. U.S.A. 84, 3415–3419. doi:
10.1073/pnas.84.10.3415
Ono, Y., and Sorimachi, H. (2012). Calpains: an elaborate proteolytic system.
Biochim. Biophys. Acta 1824, 224–236. doi: 10.1016/j.bbapap.2011.08.005
Otth, C., Concha, I. I., Arendt, T., Stieler, J., Schliebs, R., Gonzalez-Billault, C., et al.
(2002). AβPP induces cdk5-dependent tau hyperphosphorylation in transgenic
mice Tg2576. J. Alzheimers Dis. 4, 417–430.
Patrick, G. N., Zhou, P., Kwon, Y. T., Howley, P. M., and Tsai, L. H. (1998). p35,
the neuronal-speciﬁc activator of cyclin-dependent kinase 5 (Cdk5) is degraded
by the ubiquitin-proteasome pathway. J. Biol. Chem. 273, 24057–24064. doi:
10.1074/jbc.273.37.24057
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., and Tsai,
L. H. (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes
neurodegeneration. Nature 402, 615–622. doi: 10.1038/45159
Patzke, H., and Tsai, L. H. (2002). Calpain-mediated cleavage of the cyclin-
dependent kinase-5 activator p39 to p29. J. Biol. Chem. 277, 8054–8060. doi:
10.1074/jbc.M109645200
Paudel, H. K., Lew, J., Ali, Z., and Wang, J. H. (1993). Brain proline-directed
protein kinase phosphorylates tau on sites that are abnormally phosphorylated
in tau associated with Alzheimer’s paired helical ﬁlaments. J. Biol. Chem. 268,
23512–23518.
Peterson, D. W., Ando, D. M., Taketa, D. A., Zhou, H., Dahlquist, F. W., and Lew, J.
(2010). No difference in kinetics of tau or histone phosphorylation by CDK5/p25
versus CDK5/p35 in vitro. Proc. Natl. Acad. Sci. U.S.A. 107, 2884–2889. doi:
10.1073/pnas.0912718107
Piedrahita, D., Hernandez, I., Lopez-Tobon, A., Fedorov, D., Obara, B., Manjunath,
B. S., et al. (2010). Silencing of CDK5 reduces neuroﬁbrillary tangles in transgenic
Alzheimer’s mice. J. Neurosci. 30, 13966–13976. doi: 10.1523/JNEUROSCI.3637-
10.2010
Plattner, F., Angelo,M., and Giese, K. P. (2006). The roles of cyclin-dependent kinase
5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281,
25457–25465. doi: 10.1074/jbc.M603469200
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., et al.
(1998). Tau is a candidate gene for chromosome 17 frontotemporal dementia.
Ann. Neurol. 43, 815–825. doi: 10.1002/ana.410430617
Prabakaran, S., Everley, R. A., Landrieu, I., Wieruszeski, J. M., Lippens, G., Steen,
H., et al. (2011). Comparative analysis of Erk phosphorylation suggests a mixed
strategy for measuring phospho-form distributions. Mol. Syst. Biol. 7, 482. doi:
10.1038/msb.2011.15
Qi, Z., Huang, Q. Q., Lee, K. Y., Lew, J., and Wang, J. H. (1995). Reconstitution
of neuronal Cdc2-like kinase from bacteria-expressed Cdk5 and an active frag-
ment of the brain-speciﬁc activator. Kinase activation in the absence of Cdk5
phosphorylation. J. Biol. Chem. 270, 10847–10854. doi: 10.1074/jbc.270.18.
10847
Quintanilla, R. A., Orellana, D. I., Gonzalez-Billault, C., and Maccioni, R.
B. (2004). Interleukin-6 induces Alzheimer-type phosphorylation of tau pro-
tein by deregulating the cdk5/p35 pathway. Exp. Cell Res. 295, 245–257. doi:
10.1016/j.yexcr.2004.01.002
Rosales, J. L., and Lee, K. Y. (2006). Extraneuronal roles of cyclin-dependent kinase
5. Bioessays 28, 1023–1034. doi: 10.1002/bies.20473
Saito, T., Ishiguro, K., Onuki, R., Nagai, Y., Kishimoto, T., and Hisanaga, S. (1998).
Okadaic acid-stimulated degradation of p35, an activator of CDK5, by protea-
some in cultured neurons. Biochem. Biophys. Res. Commun. 252, 775–778. doi:
10.1006/bbrc.1998.9739
Sakaue, F., Saito, T., Sato, Y., Asada, A., Ishiguro, K., Hasegawa, M., et al.
(2005). Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase
5 complexed with p35, p25, or p39. J. Biol. Chem. 280, 31522–31529. doi:
10.1074/jbc.M504792200
Sengupta, A., Wu, Q., Grundke-Iqbal, I., Iqbal, K., and Singh, T. J. (1997). Potentia-
tion of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5.
Mol. Cell. Biochem. 167, 99–105. doi: 10.1023/A:1006883924775
Sharma, P., Steinbach, P. J., Sharma, M., Amin, N. D., Barchi, J. J. Jr., and Pant, H.
C. (1999). Identiﬁcation of substrate binding site of cyclin-dependent kinase 5. J.
Biol. Chem. 274, 9600–9606. doi: 10.1074/jbc.274.14.9600
Shetty, K. T., Link, W. T., and Pant, H. C. (1993). cdc2-like kinase from rat
spinal cord speciﬁcally phosphorylates KSPXK motifs in neuroﬁlament proteins:
isolation and characterization. Proc. Natl. Acad. Sci. U.S.A. 90, 6844–6848. doi:
10.1073/pnas.90.14.6844
Shukla, V., Skuntz, S., and Pant, H. C. (2012). Deregulated Cdk5 activity is
involved in inducing Alzheimer’s disease. Arch. Med. Res. 43, 655–662. doi:
10.1016/j.arcmed.2012.10.015
Smet, C., Sambo, A. V., Wieruszeski, J. M., Leroy, A., Landrieu, I., Buee, L., et al.
(2004). The peptidyl prolyl cis/trans-isomerase Pin1 recognizes the phospho-
Thr212-Pro213 site on Tau. Biochemistry 43, 2032–2040. doi: 10.1021/bi0
35479x
Sontag, J. M., and Sontag, E. (2014). Protein phosphatase 2A dysfunction in
Alzheimer’s disease. Front. Mol. Neurosci. 7:16. doi: 10.3389/fnmol.2014.00016
Spillantini, M. G., Bird, T. D., and Ghetti, B. (1998). Frontotemporal dementia
and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain
Pathol. 8, 387–402. doi: 10.1111/j.1750-3639.1998.tb00162.x
Spillantini, M. G., and Goedert, M. (2013). Tau pathology and neurodegeneration.
Lancet Neurol. 12, 609–622. doi: 10.1016/S1474-4422(13)70090-5
Takashima, A., Murayama, M., Yasutake, K., Takahashi, H., Yokoyama, M., and
Ishiguro, K. (2001). Involvement of cyclin dependent kinase5 activator p25 on tau
phosphorylation in mouse brain. Neurosci. Lett. 306, 37–40. doi: 10.1016/S0304-
3940(01)01864-X
Tanemura, K., Murayama, M., Akagi, T., Hashikawa, T., Tominaga, T., Ichikawa, M.,
et al. (2002). Neurodegeneration with tau accumulation in a transgenic mouse
expressing V337M human tau. J. Neurosci. 22, 133–141.
Tang, D.,Yeung, J., Lee, K.Y.,Matsushita,M.,Matsui, H., Tomizawa, K., et al. (1995).
An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J. Biol.
Chem. 270, 26897–26903. doi: 10.1074/jbc.270.45.26897
Tarricone, C., Dhavan, R., Peng, J., Areces, L. B., Tsai, L. H., and Musacchio, A.
(2001). Structure and regulation of the CDK5-p25nck5a complex. Mol. Cell 8,
657–669. doi: 10.1016/S1097-2765(01)00343-4
Tatebayashi, Y., Miyasaka, T., Chui, D. H., Akagi, T., Mishima, K., Iwasaki, K.,
et al. (2002). Tau ﬁlament formation and associative memory deﬁcit in aged
Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 65 | 9
Kimura et al. Phosphorylation of tau by Cdk5
mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U.S.A. 99,
13896–13901. doi: 10.1073/pnas.202205599
Tsai, L. H., Delalle, I., Caviness, V. S. Jr., Chae, T., and Harlow, E. (1994). p35 is
a neural-speciﬁc regulatory subunit of cyclin-dependent kinase 5. Nature 371,
419–423. doi: 10.1038/371419a0
Uchida, T., Ishiguro, K., Ohnuma, J., Takamatsu, M., Yonekura, S., and Imahori,
K. (1994). Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase
II: its sequence and developmental change in brain. FEBS Lett. 355, 35–40. doi:
10.1016/0014-5793(94)01163-X
Vandebroek, T., Vanhelmont, T., Terwel, D., Borghgraef, P., Lemaire, K., Snauwaert,
J., et al. (2005). Identiﬁcation and isolation of a hyperphosphorylated, con-
formationally changed intermediate of human protein tau expressed in yeast.
Biochemistry 44, 11466–11475. doi: 10.1021/bi0506775
Vanhelmont, T., Vandebroek, T., De Vos, A., Terwel, D., Lemaire, K., Anandhaku-
mar, J., et al. (2010). Serine-409 phosphorylation and oxidative damage deﬁne
aggregation of human protein tau in yeast. FEMS Yeast Res. 10, 992–1005. doi:
10.1111/j.1567-1364.2010.00662.x
Wada, Y., Ishiguro, K., Itoh, T. J., Uchida, T., Hotani, H., Saito, T., et al. (1998).
Microtubule-stimulated phosphorylation of tau at Ser202 and Thr205 by cdk5
decreases its microtubule nucleation activity. J. Biochem. 124, 738–746. doi:
10.1093/oxfordjournals.jbchem.a022174
Watanabe, A., Hasegawa, M., Suzuki, M., Takio, K., Morishima-Kawashima, M.,
Titani, K., et al. (1993). In vivo phosphorylation sites in fetal and adult rat tau. J.
Biol. Chem. 268, 25712–25717.
Wen, Y., Planel, E., Herman, M., Figueroa, H. Y., Wang, L., Liu, L., et al. (2008).
Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3β
mediated by neuregulin signaling leads to differential effects on tau phosphory-
lation and amyloid precursor protein processing. J. Neurosci. 28, 2624–2632. doi:
10.1523/JNEUROSCI.5245-07.2008
Wen, Y., Yang, S. H., Liu, R., Perez, E. J., Brun-Zinkernagel, A. M., Koulen,
P., et al. (2007). Cdk5 is involved in NFT-like tauopathy induced by transient
cerebral ischemia in female rats. Biochim. Biophys. Acta 1772, 473–483. doi:
10.1016/j.bbadis.2006.10.011
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T.
C., et al. (2007). Synapse loss and microglial activation precede tangles in a
P301S tauopathy mouse model. Neuron 53, 337–351. doi: 10.1016/j.neuron.2007.
01.010
Yotsumoto, K., Saito, T., Asada, A., Oikawa, T., Kimura, T., Uchida, C., et al. (2009).
Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant
Tau. J. Biol. Chem. 284, 16840–16847. doi: 10.1074/jbc.M109.003277
Yu,Y., Run,X., Liang, Z., Li,Y., Liu, F., Liu,Y., et al. (2009). Developmental regulation
of tau phosphorylation, tau kinases, and tau phosphatases. J. Neurochem. 108,
1480–1494. doi: 10.1111/j.1471-4159.2009.05882.x
Zempel, H., Thies, E., Mandelkow, E., and Mandelkow, E. M. (2010). Aβ oligomers
cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites,
Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci.
30, 11938–11950. doi: 10.1523/JNEUROSCI.2357-10.2010
Zheng, M., Leung, C. L., and Liem, R. K. (1998). Region-speciﬁc expression of
cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the devel-
oping and adult rat central nervous system. J. Neurobiol. 35, 141–159. doi:
10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4
Zheng, Y. L., Amin, N. D., Hu, Y. F., Rudrabhatla, P., Shukla, V., Kanungo, J., et al.
(2010). A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator,
speciﬁcally inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J.
Biol. Chem. 285, 34202–34212. doi: 10.1074/jbc.M110.134643
Zheng, Y. L., Kesavapany, S., Gravell, M., Hamilton, R. S., Schubert, M., Amin, N.,
et al. (2005). A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and
apoptosis in neurons. EMBO J. 24, 209–220. doi: 10.1038/sj.emboj.7600441
Conflict of Interest Statement:The authors declare that the research was conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 23 May 2014; accepted: 26 June 2014; published online: 15 July 2014.
Citation: Kimura T, Ishiguro K andHisanaga S-i (2014) Physiological and pathological
phosphorylation of tau by Cdk5. Front. Mol. Neurosci. 7:65. doi: 10.3389/fnmol.
2014.00065
This article was submitted to the journal Frontiers in Molecular Neuroscience.
Copyright © 2014 Kimura, Ishiguro and Hisanaga. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 65 | 10
